Angiogenesis Inhibitors: all 4,430 studies that test it
Page 2 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.
- Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.RecruitingNCT07407465Phase 2
- Efficacy of Faricimab in Patients With Subretinal Hyper-reflective MaterialRecruitingNCT07403825Phase 4
- Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard TherapyRecruitingNCT07397819Phase 1/2
- LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS MutationNot yet recruitingNCT07391566Phase 1/2
- Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS TrialRecruitingNCT07389980Phase 3
- Combining Latency Reversing Agents to Address the HIV ReservoirNot yet recruitingNCT07384624Phase 1/2
- Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular DegenerationRecruitingNCT07367282Phase 4
- IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric CancerNot yet recruitingNCT07361991Phase 1/2
- Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBCEnrolling by invitationNCT07359404Phase 2
- MA-CRC-II-016 SHR-1811Not yet recruitingNCT07355764Phase 2
- Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual DiseaseRecruitingNCT07346157Phase 1/2
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingNCT07341867Phase 1
- Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular EdemaEnrolling by invitationNCT07338097Not applicable
- A Multi-Arm, Platform Trial For Relapsed NeuroblastomaRecruitingNCT07334301Phase 1/2
- QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTTRecruitingNCT07327788Phase 2
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
- A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07312188Phase 2
- A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07309419Phase 2/3
- Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract SurgeryNot yet recruitingNCT07301775Phase 4
- Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular LymphomaRecruitingNCT07299149Phase 2
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingNCT07288034Phase 2
- A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.RecruitingNCT07283367Phase 1/2
- Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07281664Not applicable
- Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and BevacizumabRecruitingNCT07276100Phase 2
- Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent GlioblastomaNot yet recruitingNCT07274787Not applicable
- Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialRecruitingNCT07263438Phase 2
- Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaRecruitingNCT07261163Phase 2
- Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaRecruitingNCT07257510Not applicable
- Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial SettingRecruitingNCT07249216Not applicable
- Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07244926Phase 2
- A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRCRecruitingNCT07244705Phase 1/2
- A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerRecruitingNCT07241767Phase 2
- The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical StudyRecruitingNCT07240194Phase 2
- Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular CarcinamoRecruitingNCT07239245Phase 2
- A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E MutationNot yet recruitingNCT07229846Phase 2
- Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and SafetyRecruitingNCT07216014Phase 4
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingNCT07213804Phase 3
- Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLRecruitingNCT07208981Phase 2
- The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal CancerRecruitingNCT07204574Phase 1/2
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingNCT07198074Phase 3
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingNCT07193862Early Phase 1
- Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & BevacizumabRecruitingNCT07192185Phase 2
- Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular NeovascularizationNot yet recruitingNCT07187804Phase 4
- Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCHRecruitingNCT07187193Phase 2
- Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman DiseaseRecruitingNCT07187167Phase 2
- High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLCNot yet recruitingNCT07182708Phase 2
- Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal CancerRecruitingNCT07150247Phase 2
- T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain MetastasisRecruitingNCT07150208Phase 2
- A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07138209Phase 3
- Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)Not yet recruitingNCT07134101Phase 2
- A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)Not yet recruitingNCT07128251Phase 2
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingNCT07126236Phase 2
- A Study of IBI363 Combination Therapy in Participants With Advanced Solid TumorsNot yet recruitingNCT07124793Phase 2
- Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein MarkerNot yet recruitingNCT07120451Phase 2
- Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian CancerNot yet recruitingNCT07117877Phase 2
- Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver MetastasesRecruitingNCT07117435Phase 1
- Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRCNot yet recruitingNCT07116577Phase 2
- Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II TrialRecruitingNCT07106034Phase 2
- Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaRecruitingNCT07096778Phase 2
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07095452Phase 2/3
- Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)Not yet recruitingNCT07089719Phase 2
- A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST TrialRecruitingNCT07074756Not applicable
- BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC PatientsNot yet recruitingNCT07071844Phase 2
- Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRCNot yet recruitingNCT07070713Phase 2
- A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related DiseaseRecruitingNCT07068165Phase 2/3
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Phase 1
- RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingNCT07065435Phase 2
- BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or OligometastasesRecruitingNCT07062055Phase 2
- An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal CancerNot yet recruitingNCT07061210Phase 2
- Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal CancerNot yet recruitingNCT07059949Phase 2
- A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerRecruitingNCT07059845Phase 2
- Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver TransplantRecruitingNCT07059494Phase 4
- FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung AdenocarcinomaRecruitingNCT07058428Phase 3
- A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial CancerRecruitingNCT07054567Phase 2
- A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian CancerRecruitingNCT07042802Phase 1/2
- Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)RecruitingNCT07025005Phase 4
- The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM PatientsNot yet recruitingNCT07015021Not applicable
- FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular CarcinomaRecruitingNCT07012798Phase 2
- QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRCNot yet recruitingNCT07009145Phase 2
- Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver MetastasisNot yet recruitingNCT07007728Phase 2
- Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical StudyNot yet recruitingNCT07004335Phase 4
- ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)RecruitingNCT06997081Phase 2
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06996782Phase 1/2
- FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver MetastasisRecruitingNCT06988852Phase 2
- A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT06986785Phase 2
- A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.Not yet recruitingNCT06982924Phase 2
- Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast CancerRecruitingNCT06976944Phase 2
- A Study to Determine the Safety and Efficacy of Bevacizumab Administered Via Injection Into the Shoulder Joint of Participants With Adhesive Capsulitis (Frozen Shoulder)RecruitingNCT06976671Phase 2
- Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple MyelomaRecruitingNCT06974786Phase 2
- Autophagy Maintenance (AUTOMAIN)RecruitingNCT06971744Phase 2
- Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus ErythematosusNot yet recruitingNCT06965244Phase 3
- Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian CancerRecruitingNCT06954584Phase 3
- Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)RecruitingNCT06952452Phase 3
- Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid TumorsRecruitingNCT06940349Phase 1/2
- Impact of Intravitreal Faricimab on Renal Function in Diabetic PatientsRecruitingNCT06929507Not applicable
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruitingNCT06918002Phase 3
- A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant TumourRecruitingNCT06915142Phase 2
- Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After RelapseRecruitingNCT06910124Phase 2
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersRecruitingNCT06906341Phase 2
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06893887Not applicable